



Published in final edited form as:

J Neurol Neuromedicine. 2016 ; 1(2): 29–36.

Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System

Alejandra N. Martinez¹ and Mario T. Philipp^{1,2,*}

¹Division of Bacteriology & Parasitology, Tulane National Primate Research Center, Covington, LA, USA

²Department of Microbiology and Immunology, Tulane University Medical School, New Orleans, LA, USA

Abstract

This review addresses the role that substance P (SP) and its preferred receptor neurokinin-1 (NK1R) play in neuroinflammation associated with select bacterial, viral, parasitic, and neurodegenerative diseases of the central nervous system. The SP/NK1R complex is a key player in the interaction between the immune and nervous systems. A common effect of this interaction is inflammation. For this reason and because of the predominance in the human brain of the NK1R, its antagonists are attractive potential therapeutic agents. Preventing the deleterious effects of SP through the use of NK1R antagonists has been shown to be a promising therapeutic strategy, as these antagonists are selective, potent, and safe. Here we evaluate their utility in the treatment of different neuroinfectious and neuroinflammatory diseases, as a novel approach to clinical management of CNS inflammation.

Keywords

Substance P; NK1R antagonist; Central Nervous System; Neuroinflammation; Neurodegeneration; Pathogens

Introduction

The SP/NK1R system plays an important role in neuroinflammation. SP is encoded by the TAC1 gene and belongs to a large family of structurally related peptides, the tachykinins. These are small peptides broadly distributed in the central (CNS) and peripheral nervous systems (PNS)¹. The major mammalian tachykinin peptides include SP, neurokinin A (NKA), and neurokinin B (NKB), together with NH₂-terminally extended forms of NKA, neuropeptide K (NPK), and neuropeptide γ (NK γ)². The primary structures of SP, NKA and NKB are very similar in all mammalian species³.

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License

*Correspondence: Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA, philipp@tulane.edu.

SP has a high affinity for the NK1 receptor, to which it binds preferentially. It also binds to the other tachykinin receptors, NK2R and NK3R, with lower affinity⁴. SP and its cognate receptors are present in neurons, as well as in microglia, endothelial cells, and peripheral immune cells⁵. Due in part to its diverse anatomical distribution, the SP/NK1R system is found to be involved in a variety of complex physiological responses including pain, emotion, neuroinflammation, and microvascular permeability. Preventing the actions of SP through the use of NK1 receptor antagonists is emerging as a promising therapeutic approach for treatment of neuroinflammatory conditions. Thus, we reviewed preclinical and clinical studies on the effectiveness of NK1R antagonist treatment of CNS inflammation due to bacterial, viral, parasitic or neurodegenerative diseases.

Structure and Processing of SP and the NK1R

SP, an undecapeptide, is derived from the preprotachykinin-A gene, which is differentially spliced to form different mRNAs⁶. It is synthesized, mostly by neurons, as a large protein, and is transported to the neuronal terminal endings, where it is enzymatically converted into the active form and stored in vesicles ready for release. Its preferred endogenous receptor, NK1R, is a G protein-coupled receptor with seven transmembrane domains and diverse downstream pathways, which vary depending upon the cell type where the receptor is located⁷. There are two NK1R isoforms: a truncated isoform (311 aa) that lacks most of the intracellular C-tail and a full-length form (407 aa). The full-length form is expressed in several brain regions, with the exception of the cerebellum. The truncated form is predominately found in peripheral tissues, elicits a diminished calcium response and has a 10-fold lower binding affinity to SP than the full-length form⁸. Upon SP stimulation, NK1R is internalized by the clathrin-dependent mechanism to the acidified endosomes, where the complex disassociates². The fate of the internalized receptor depends on the stimulation conditions. Thus, low concentrations of SP lead to its degradation and recycling of NK1R to the cell surface. Conversely, after sustained incubation with high SP concentrations, as may occur during inflammation, NK1R is ubiquitinated and degraded².

Neuroinflammation and Substance P

Acute insults to the CNS can be caused by injury or infection and are usually accompanied by inflammatory responses. Classical neuroinflammatory responses are characterized by glial activation, proliferation of microglia, leukocyte recruitment, and up-regulation and secretion of mediators such as cytokines and chemokines⁹. SP plays a major pathogenic role as it is an important mediator of both inflammation and increased blood-brain barrier (BBB) permeability in the CNS¹⁰. In addition, SP is a potent initiator of neurogenic inflammation, which differs from classical inflammation in that it is neurally elicited and results in vasodilation, plasma extravasation, tissue swelling, mast cell degranulation, and increased permeability of the BBB through the release of neuropeptides^{4,11}. In this context, SP is increasingly being recognized as an important element in the pathogenesis of many neurological diseases.

SP is widely distributed throughout the CNS, PNS, and enteric nervous systems. It is present in dorsal root ganglia (primary sensory) neurons¹², as well as in many regions of the CNS,

including the hippocampus, cortex, basal ganglia, hypothalamus, amygdala, caudate nucleus, and spinal cord. It is more abundant in the grey matter, more specifically, in the substantia nigra (SN), which contains a disproportionately high density of microglia¹³. Therefore, SP and its preferred receptor, NK1R, are key mediators in the interaction between the immune and nervous systems.

SP signaling can activate different pathways depending on the cell type involved². Once released, SP may have direct post-synaptic actions as a neurotransmitter, modulatory function at post-synaptic sites, or other functions on nonneuronal targets^{11,14}. The major pathways activated by the SP/NK1R complex lead to phosphoinositide hydrolysis, calcium mobilization, and mitogen-activated protein kinase (MAPK) activation^{15,16}. These pathways are involved in neuroinflammation, neuronal excitation, cell survival and cell migration^{14,17,18}. SP is capable of activating NFkB, which affects the regulation of various inflammatory genes, thus explaining its effects on chemotaxis and other inflammatory mechanisms¹⁹. The role of SP can be best described as that of a pleiotropic immune regulator.

SP exacerbates neurodegeneration in several neuroinflammatory conditions that are initiated in response to a variety of cues, including infection with bacteria, viruses, or parasites, traumatic brain injury, toxic metabolites, or autoimmunity²⁰. There are unique relationships between tachykinins and CNS invasion by bacteria. Studies involving bacterial infections have shown that SP can synergistically augment *Borrelia burgdorferi* induced expression of COX-2 in murine microglia²¹, and that endogenous SP/NK1R interactions are required for maximal inflammatory responses to *in vivo* challenge with bacteria such as *Neisseria meningitidis* or *B. burgdorferi*^{22,23}. Similarly, the interaction of *B. burgdorferi* with cultured rhesus macaque DRG neurons and DRG tissue explants in the presence and absence of an NK1R antagonist indicated that activation of the NK1R by SP may contribute to the pathophysiology of Lyme neuroborreliosis²³. Also, SP has been shown to enhance inflammatory glial responses to *Streptococcus pneumoniae*, the major Gram-positive causative agent of bacterial meningitis²².

SP has also been studied in the context of neuroparasitic infections. It has been linked to the induction of seizures in a rodent model of neurocysticercosis (NCC), caused by the helminth *Taenia crassiceps*²⁴. SP was also implicated in the development of post-treatment inflammatory encephalopathy (PTRE) in a murine model of *Trypanosoma brucei* infection. This model shows remarkable similarities to the pathology seen in the CNS of individuals with African trypanosomiasis, also known as sleeping sickness^{25,26}. The effect of SP on viruses that cause neurocognitive impairment, such as human immunodeficiency virus (HIV) has also been investigated. An *in vitro* study using human fetal brain cell cultures expressing full-length NK1R showed that SP enhances HIV-1 infection²⁷. Likewise, *in vivo* studies demonstrated that SP drives macrophage polarization and inflammation in HIV patients with neurocognitive impairment²⁸⁻³⁰. Together, these studies confirm that higher levels of SP are associated with exacerbation of the neuroinflammatory process.

Traditionally defined neuroinflammatory diseases (such as multiple sclerosis [MS] or encephalitides) are often distinguished from neurodegenerative diseases, such as Alzheimer's

disease (AD) or Parkinson's disease (PD), based on what kind of inflammation they evoke. Thus, tissue invasion of blood-derived leukocytes of the adaptive immune system (T and B lymphocytes) is prominent in MS and widely accepted to be disease-promoting³¹. In contrast, the pathogenesis of PD and AD are thought to be naturally occurring processes that involve innate components such as microglia, astrocytes, the complement system, and cytokines³². The immunomodulatory properties of SP and its role in autoimmune neuroinflammation have been investigated in more detail using the experimental autoimmune encephalomyelitis (EAE) model, as it resembles MS^{33,34}. This EAE model features inflammation of complex pathogenesis, demyelination, which is the hallmark of MS, axonal loss or damage, and gliosis³⁴. Studies confirmed that SP-mediated signaling contributes to the maintenance of inflammation in the CNS during the chronic phase of EAE³⁵ and likely stimulates Th1 and Th17 autoreactive cells. These migrate to the CNS, enhance BBB crossing, and perpetuate inflammation¹⁹. Additionally, genome-wide linkage studies provided data to suggest that the SP precursor protein-encoding TAC1 gene is a possible susceptibility gene for MS^{36,37}.

PD is the most common motor neurodegenerative disorder affecting approximately 4 million people worldwide. It is characterized by loss of dopaminergic neurons in the SN, an integral part of the basal ganglia^{38,39}. High levels of SP are present in the SN, where it binds to NKIRs expressed on dopaminergic neurons. Subsequent internalization of the SP/NK1R complex activates a cascade of events that lead to the release of dopamine into the striatum⁴⁰. SP and dopamine regulation work in a positive feedback mechanism as dopamine can potentiate the release of SP^{38,41}. Therefore, SP decline is seen in postmortem PD brains and in models that replicate the late stages of the disease⁴²⁻⁴⁴, as a secondary effect of dopaminergic degeneration. The functional role of SP in the regulation of neuroinflammation and dopaminergic neuron survival remains elusive. One study showed that SP helps to restore dopamine deficit in the brain in an animal model of PD⁴⁵. Others have shown that exacerbation of SP levels accelerate PD progression^{13,38}. These discrepancies might be the result of different study designs, where the suggested beneficial role of SP is based on a short-term analysis of early disease stage that only contemplated dopamine deficit restoration by SP. The downstream effects of early SP exacerbation in PD include nigral BBB breakdown through neurogenic inflammation, as well as local inflammatory response, and are therefore detrimental. A noteworthy recent finding showed that the most effective drug in the treatment of PD, levodopa (L-3,4-dihydroxyphenylalanine or L-DOPA), increases nigral SP levels³⁹.

Current findings on the neuroinflammatory process in AD have suggested a neuroprotective role of SP. This contrasts with the detrimental effect observed in MS. AD is the most common neurodegenerative disorder. It is characterized by the formation of neurofibrillary tangles in the cortex, which are mainly constituted by altered phosphorylated and truncated portions of tau protein and by abnormal extracellular deposition of neurotoxic beta amyloid (A β) peptides⁴⁶. Reduced SP levels were found in cortical regions of post-mortem brain tissues of patients suffering from AD^{47,48} but conflicting results were obtained regarding SP levels in the CSF, where they were elevated or reduced depending on the study⁴⁹⁻⁵¹. Transgenic mouse models of AD based on the known genetic origins of familial AD have significantly contributed to the understanding of the molecular mechanisms involved in the

onset and progression of the disease⁵². Studies using animal models showed that administration of SP provides protection from the cognitive impairment induced by A β infusion⁵³, prevents A β induced neuronal loss⁵⁴ and improves memory functions⁵⁵. Despite the observed benefits, it is unlikely that administration of SP will be used as a treatment of AD as it induces multiple effects including risk of emesis and nausea.

NK1R Antagonists in Neuroinflammation

Specific NK1R antagonists block binding of SP to its receptor. Several NK1R antagonists have been investigated and show promise for neuroinfectious and neuroinflammatory disease treatment. Different compounds have been developed by various pharmaceutical companies but the only NK1R antagonist that is currently approved for clinical use is aprepitant (Emend)⁵⁶. Fosaprepitant (Emend for injection), a water-soluble phosphoryl prodrug for intravenous use, is also available and is marketed as Ivemend⁵⁷. These drugs are well tolerated and used as antiemetics to combat chemotherapy-induced nausea in cancer patients¹¹. Investigators have focused on the use of NK1R antagonists as an alternative to classical anti-inflammatory drugs. The antagonists have the advantage of targeting chronic inflammation without impairing acute immune responses. In addition, nonpeptide NK1R antagonists can cross the BBB and exert CNS effects¹⁵.

NK1R Antagonists and CNS-Invasive Bacteria

Studies have shown that systemic administration of the NK1R antagonist L703,606 oxalate significantly inhibits *N. meningitidis* and *B. burgdorferi* induced CNS gliosis, demyelination, and associated inflammatory cytokine elevations in a murine model, while attenuating concomitant decreases in IL-10 levels⁵⁸. The therapeutic potential of L703,606 oxalate was also tested in a murine model of pneumococcal meningitis²⁰. Results showed that pharmacological targeting of the NK1R prevented the development of damaging inflammation when administered prophylactically, and limited neuroinflammation associated with *S. pneumonia* infection. In addition, it was demonstrated that this therapeutic intervention was capable of reversing infection-associated gliosis and demyelination²². In line with these findings, primary explant cultures from nonhuman primate brain and dorsal root ganglia infected with *B. burgdorferi* and treated with L703,606 oxalate showed significantly decreased levels of proinflammatory cytokines (IL-6, CXCL8, CCL2), as well as decreased oligodendrocyte and neuronal apoptosis, compared to untreated explant cultures²³. CCL2/CCR2 and MAPK, chiefly MEK/ERK, signaling play a major role in neuroinflammation^{59,60} and SP is known to selectively enhance inflammatory chemokine production via ERK/p38 MAPK-mediated NF- κ B activation^{13,61}. Hence, this result is consistent with the possibility that blockage of NK1R may act by limiting these signaling cascades and extends prior work in murine models, which showed that SP/NK1R interactions are required *in vivo* for inflammation after challenge with bacteria.

NK1R Antagonists and CNS-Invasive Parasites

As mentioned, SP is present in the brain of NCC patients and co-localizes with areas of inflammation adjacent to degenerating worms²⁴. Studies using *T. crassiceps* infected mice showed that, similar to *T. solium* infection in humans, cysts cause little or no inflammation,

while dead or dying parasites initiate a granulomatous reaction. SP was shown to be required to generate epileptogenic granuloma extracts, and the NK1 receptor was required to respond to these extracts with seizure activity⁶². This notion led to the investigation of NK1R antagonists as potential treatment to prevent seizures. Therefore, in a mouse model of NCC, pretreatment with aprepitant resulted in complete abrogation of seizure activity. These findings suggest that NK1R antagonists may be used to prevent and/or treat seizures in NCC in humans and, perhaps, function as an adjuvant or replacement for the treatment of these seizures with antiepileptic drugs²⁴.

A study of a mouse model of PTRE demonstrated that SP plays an important role in this phenomenon²⁶. This model reproduces the effects of human African trypanosomiasis in the CNS at a late stage of the disease that is characterized by fatal encephalopathy. The experimental design consisted in infecting mice with the protozoan parasite *Trypanosoma brucei* and treating them subcuratively with the trypanocidal drug diminazene aceturate, to induce an acute inflammatory meningoencephalitis. Treatment with RP67,580, a NK1R antagonist, showed reduction in the severity of the inflammatory response and the degree of astrocyte activation in the brain²⁵. These findings pointed to the development of novel anti-inflammatory therapies in human African trypanosomiasis by modulating NK1R-mediated responses.

NK1R Antagonists and CNS-Invasive Viruses

Patients with HIV infection, even if successfully treated, may have a high frequency of neurocognitive impairment that is associated with residual chronic inflammation. Studies have shown elevated levels of SP in the sera of HIV patients³ and simian immune deficiency (SIV)-infected rhesus macaques⁶³. SP facilitates HIV replication, and reciprocally, NK1R antagonists block HIV in part through the co-receptor CCR5, as well as through blocking SP-driven macrophage polarization and inflammation²⁹. Initial *in vitro* studies using the NK1R antagonists CP-96,345 and aprepitant led to further investigation of NK1R antagonists as potential HIV therapeutic and immunomodulatory agents^{64,65}. A phase 1B randomized, placebo controlled, double-masked study to evaluate the safety, antiviral activity, pharmacokinetics, and immune-modulatory effects of aprepitant in HIV-infected adults revealed that aprepitant was safe but did not show significant antiviral or immunologic improvement at the doses used (125 or 250 mg for 14 days and follow-up study for 42 days)³⁰. A subsequent clinical trial increased the aprepitant dose to 375mg per day in order to determine its *in vivo* safety, antiviral activity and the effect on inflammatory markers²⁸ in HIV patients not receiving antiretroviral therapy. Despite the higher dose used, aprepitant did not show a significant antiviral activity but the investigators believe that this dose is still too low based on the target concentrations required to elicit an antiviral effect in *in vitro* and preclinical experiments. Aprepitant treatment was, however, associated with decreased programmed death-1 (PD-1) expression on CD4+ T cells, and decreased plasma levels of SP and soluble CD163 (an indicator of monocyte activation) [28], which are markers associated with poor disease prognosis. In addition, when the results of both studies were combined (125–250–375 mg) a significant reduction in plasma levels of several pro-inflammatory cytokines including IL-6 and TNF α was observed. These results are encouraging and suggest that blockade of the NK1R pathway has a role in modulating

monocyte activation in HIV infection. Hence, prospective studies to evaluate the immunomodulatory and anti-inflammatory effects of Aprepitant with longer treatment (4 weeks) and co-administration with ritonavir to boost Aprepitant plasma concentrations in virologically suppressed patients on combination antiretroviral therapy are ongoing (ClinicalTrials.gov # NCT02154360).

NK1R Antagonists and Neurodegenerative Diseases

MS is an inflammatory demyelinating disease and, at least in part, an immune-mediated disease where both innate and adaptive immune responses play a role⁶⁶. SP-reactive cells are found in MS lesions, where they enhance proinflammatory cytokine production by T cells. Activated T cells can then produce more SP, up-regulate NK1R, and stimulate antigen presenting cells to produce further T cell stimulatory cytokines. This positive feedback leads to an up-regulation of Th1 and Th17 responses, enhanced BBB permeability and perpetuation of inflammation¹⁹. Studies in the MS murine model EAE show evidence that SP-mediated signaling contributes to the maintenance of inflammation in the CNS during the chronic phase of the disease. Consequently, the genetic absence of NK1R or its suppression using the synthetic antagonist SR140333 showed beneficial effects in the chronic stages of the disease, but not during the acute phase³⁵. Similarly, in a different study using the EAE model, the authors evaluated the effect of CP-96,345, a selective NK1R antagonist, and found marked suppression of clinical and histological signs of EAE after early treatment, although severity could not be modulated if treatment was started at the peak of disease⁶⁷. The beneficial anti-inflammatory effects of antagonist treatment consisted in the decreased expression of adhesion molecules in CNS endothelia, and reduced secretion of proinflammatory Th1 cytokines⁶⁵. Another study that used human peripheral blood mononuclear cells (PBMCs) evaluated the interactions of SP and NK1R with the IL-12/IL-23 family of cytokines and the associated IFN- γ /IL-17 in the context of MS. Treatment of PBMCs with the specific NK1R antagonist CP-96,345 suppressed the up-regulation of IL-12 and IL-23 that was induced by SP stimulation¹⁹. Given the similarity of the *in vitro* results with those from the experiments in mice it is possible to suggest that NK1R antagonists are therapeutic candidates in MS.

The neurotoxic 6-hydroxydopamine (6-OHDA) lesion model is the classic and frequently utilized animal model of PD, as it produces oxidative stress and causes cell death in dopamine neuronal populations. SP expression was shown to be elevated following 6-OHDA treatment of dopaminergic neurons *in vitro*⁶⁸ and, comparably, increased SP levels were found in the SN of the rat model³⁹. This early increase of SP level was associated with augmented BBB permeability, microglial and astrocyte activation, increased dopaminergic cell death and profound motor deficit. Moreover, intrastriatal 6-OHDA injections combined with endogenous SP treatment accelerated disease progression, while blocking SP effects with NK1R antagonists (N-acetyl-L-tryptophan [NAT] or L-733,060) preserved barrier integrity, reduced inflammatory processes, attenuated 6-OHDA-induced cell death and resulted in a significant improvement in motor function³⁸. In another study, SP was able to modulate microglial function via both NK1R dependent and independent mechanisms, depending on its concentration¹³. These findings suggest that SP could use different

signaling pathways to produce proinflammatory and neurotoxic effects and, therefore, the use of NK1R antagonists would not be as effective.

The role of SP in the onset of L-DOPA induced dyskinesia (LID) or involuntary abnormal movements was also investigated. L-DOPA, the precursor to dopamine, combined with a peripheral L-DOPA decarboxylase inhibitor such as benserazide, is the gold-standard treatment for PD and results in maladaptive changes to brain signaling pathways and LID⁶⁹. Confirmation that SP is involved in the onset of LID was reported recently in an *in vivo* study where the combined administration of the NK1R antagonist N-acetyl-L-tryptophan with L-DOPA prevented the onset of mild to moderate LID⁷⁰. To corroborate this finding another group showed that treatment with a different NK1R antagonist (LY303870) was also capable of reducing LID in a rodent model by preventing dopamine efflux and the subsequent increase in secondary messenger systems³⁹. Importantly, both studies confirmed that NK1R antagonists do not interfere with L-DOPA-induced improvement in motor function. Taken together, these results suggest the use of NK1R antagonists as a novel adjunct therapy to L-DOPA in the treatment of PD.

To our knowledge there are no published studies involving AD and NK1R antagonists. However, several reports have indicated that SP has a beneficial rather than a detrimental role in AD. Very recently, a study in humans showed that patients with early AD had elevated CSF SP levels, which correlated with biomarkers of AD. This can possibly represent a compensatory mechanism to protect the AD brain from uncontrolled A β exposure⁵¹. Future experiments are still needed to further explore the interaction between beta-amyloid deposits and SP.

Conclusion

The use of classical anti-inflammatory drugs for the treatment of acute and chronic CNS diseases is often limited by detrimental side effects. NK1 receptor antagonist treatment is an appealing alternative. However, there are still many challenges in developing NK1R antagonists to treat neuroinflammation, as many neuroinflammatory diseases present complex pathologies. In addition, the extrapolation from animal to human studies is complicated by the differences in the potency with which certain antagonists interact with NK1Rs of different species². For this reasons, interpretation of the effects of NK1R receptor antagonists in preclinical assays requires great caution. Also, when one receptor is antagonized, the other two (NK2R and NK3R) may compensate for this effect⁷¹. Therefore, antagonists that target more than one NK receptor could be needed. Overall, however, the use of NK1R antagonists appears to be a promising therapeutic approach for neuroinflammatory diseases of diverse etiologies.

Acknowledgements

This project was supported by grant NS050325 from the National Institute of Neurologic Disorders and Stroke and by grant P510D011104/P51RR000164 from the National Center for Research Resources and the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health.

References

1. Mantyh PW. Neurobiology of substance P and the NK1 receptor. *J Clin Psychiatry*. 2002; 11:6–10. [PubMed: 12562137]
2. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. *Physiol Rev*. 2014; 94:265–301. [PubMed: 24382888]
3. Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. *Ann N Y Acad Sci*. 2011; 1217:83–95. [PubMed: 21091716]
4. Corrigan F, Vink R, Turner RJ. Inflammation in acute CNS injury: a focus on the role of substance P. *Br J Pharmacol*. 2016; 173:703–15. [PubMed: 25827155]
5. Janson CG. Blocking Borrelia in the brain. *Sci Transl Med*. 2016; 8:324ec18–324ec18.
6. Marriott I. The role of tachykinins in central nervous system inflammatory responses. *Front Biosci*. 2004; 9:2153–65. [PubMed: 15353277]
7. Garland AM, Grady EF, Payan DG, Vigna SR, Bunnett NW. Agonist-induced internalization of the substance P (NK1) receptor expressed in epithelial cells. *Biochem J*. 1994; 303:177–86. [PubMed: 7524481]
8. Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, et al. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. *Eur J Neurosci*. 2003; 17:1736–46. [PubMed: 12752772]
9. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. *Neurotherapeutics*. 2010; 7:22–30. [PubMed: 20129494]
10. Annunziata P, Cioni C, Santonini R, Paccagnini E. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. *J Neuroimmunol*. 2002; 131:41–9. [PubMed: 12458035]
11. Lewis KM, Turner RJ, Vink R. Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system. *Int J Inflam*. 2013; 2013:578480. [PubMed: 23819099]
12. Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. *J Intern Med*. 2001; 249:27–40. [PubMed: 11168782]
13. Wang Q, Chu C-H, Qian L, Chen S-H, Wilson B, Oyarzabal E, et al. Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. *J Neurosci*. 2014; 34:12490–503. [PubMed: 25209287]
14. Turner RJ, Vink R. NK1 tachykinin receptor treatment is superior to capsaicin pre-treatment in improving functional outcome following acute ischemic stroke. *Neuropeptides*. 2014; 48:267–72. [PubMed: 25151181]
15. Rosso M, Muñoz M, Berger M. The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer. *Sci World J*. 2012; 2012:1–21.
16. Bouzas-Rodríguez J, Zárraga-Granados G, Sánchez-Carbente M del R, Rodríguez-Valentín R, Gracida X, Anell-Rendón D, et al. The nuclear receptor NR4A1 induces a form of cell death dependent on autophagy in mammalian cells. *PLoS One*. 2012; 7:e46422. [PubMed: 23071566]
17. Castro-Obregón S, Del Rio G, Chen SF, Swanson RA, Frankowski H, Rao RV, et al. A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. *Cell Death Differ*. 2002; 9:807–17. [PubMed: 12107824]
18. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. *Eur J Pharmacol*. 1999; 375:51–60. [PubMed: 10443564]
19. Vilisaar J, Kawabe K, Braitch M, Aram J, Furtun Y, Fahey AJ, et al. Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFN γ /IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. *J Neuroimmune Pharmacol*. 2015; 10:457–67. [PubMed: 25690155]
20. Gendelman HE. Neural immunity: Friend or foe? *J Neurovirol*. 2002; 8:474–9. [PubMed: 12476342]

21. Rasley A, Marriott I, Halberstadt CR, Bost KL, Anguita J. Substance P augments *Borrelia burgdorferi*-induced prostaglandin E2 production by murine microglia. *J Immunol.* 2004; 172:5707–13. [PubMed: 15100316]
22. Chauhan VS, Kluttz JM, Bost KL, Marriott I. Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. *J Immunol.* 2011; 186:7255–63. [PubMed: 21562162]
23. Martinez AN, Ramesh G, Jacobs MB, Philipp MT. Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis. *J Neuroinflammation.* 2015; 12:243. [PubMed: 26714480]
24. Robinson P, Garza A, Weinstock J, Serpa J a, Goodman JC, Eckols KT, et al. Substance P causes seizures in neurocysticercosis. *PLoS Pathog.* 2012:8.
25. Kennedy PG, Rodgers J, Jennings FW, Murray M, Leeman SE, Burke JM. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to *Trypanosoma brucei*. *Proc Natl Acad Sci U S A.* 1997; 94:4167–70. [PubMed: 9108123]
26. Kennedy PGE, Rodgers J, Bradley B, Hunt SP, Gettinby G, Leeman SE, et al. Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. *Brain.* 2003; 126:1683–90. [PubMed: 12805119]
27. Schwartz L, Spitsin SV, Meshki J, Tuluc F, Douglas SD, Wolfe JH. Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor. *J Neurovirol.* 2013; 19:219–27. [PubMed: 23765222]
28. Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, et al. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of Aprepitant in HIV-1-infected adults. *AIDS.* 2015; 29:931–9. [PubMed: 25915168]
29. Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, et al. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist Aprepitant and synergistic interactions with other antiretrovirals. *AIDS.* 2010; 24:2789–96. [PubMed: 20975512]
30. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, et al. A randomized, placebo controlled, double masked phase 1B study evaluating the safety and antiviral activity of Aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. *PLoS One.* 2011; 6:e24180. [PubMed: 21931661]
31. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci.* 2015; 16:358–372. [PubMed: 25991443]
32. Alam Q, Alam MZ, Mushtaq G, Damanhoury GA, Rasool M, Kamal MA, et al. Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. *Curr Pharm Des.* 2016; 22:541–8. [PubMed: 26601965]
33. 't Hart BA, Gran B, Weissert R. EAE: imperfect but useful models of multiple sclerosis. *Trends Mol Med.* 2011; 17:119–25. [PubMed: 21251877]
34. Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). *Br J Pharmacol.* 2011; 164:1079–106. [PubMed: 21371012]
35. Reinke EK, Johnson MJ, Ling C, Karman J, Lee J, Weinstock J V, et al. Substance P receptor mediated maintenance of chronic inflammation in EAE. *J Neuroimmunol.* 2006; 180:117–25. [PubMed: 16942803]
36. Cunningham S, Patterson CC, McDonnell G, Hawkins S, Vandenbroeck K. Haplotype analysis of the preprotachykinin-1 (TAC1) gene in multiple sclerosis. *Genes Immun.* 2005; 6:265–70. [PubMed: 15729363]
37. Vandenbroeck K, Fiten P, Heggarty S, Goris A, Cocco E, Hawkins SA, et al. Chromosome 7q21-22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. *J Neuroimmunol.* 2002; 125:141–8. [PubMed: 11960650]
38. Thornton E, Vink R. Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastratial 6-Hydroxydopamine Model of Early Parkinson's Disease. *PLoS One.* 2012; 7:e34138. [PubMed: 22485158]

39. Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, et al. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. *Exp Neurol*. 2015; 271:168–74. [PubMed: 26001615]
40. Lévesque M, Wallman MJ, Parent R, Sfik A, Parent A. Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. *Neurosci Res*. 2007; 57:362–371. [PubMed: 17134780]
41. Reid MS, Herrera-Marschitz M, Hökfelt T, Lindfors N, Persson H, Ungerstedt U. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. *Exp Brain Res*. 1990; 82:293–303. [PubMed: 1704847]
42. Sivam SP. Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains. *Neuropeptides*. 1991; 18:201–7. [PubMed: 1711165]
43. Fernandez A, de Ceballos ML, Jenner P, Marsden CD. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. *Neuroscience*. 1994; 61:73–9. [PubMed: 7969897]
44. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. *Prog Neurobiol*. 1996; 50:275–331. [PubMed: 8971983]
45. Krasnova IN, Bychkov ER, Lioudyno VI, Zubareva OE, Dambinova SA. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. *Neuroscience*. 2000; 95:113–7. [PubMed: 10619467]
46. Cinzia S, Carla P, Pietro C. Substance P and Alzheimer's disease: emerging novel roles. *Curr Alzheimer Res*. 2016
47. Beal MF, Mazurek MF. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. *Neurology*. 1987; 37:1205–1205. [PubMed: 2439949]
48. Quigley BJ, Kowall NW. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. *Neuroscience*. 1991; 41:41–60. [PubMed: 1711654]
49. Cramer H, Schaudt D, Rissler K, Strubel D, Warter JM, Kuntzmann F. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. *J Neurol*. 1985; 232:346–51. [PubMed: 2416886]
50. Rösler N, Wichart I, Jellinger KA. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. *J Neural Transm*. 108:231–46. 200. [PubMed: 11314776]
51. Johansson P, Almqvist EG, Wallin A, Johansson J-O, Andreasson U, Blennow K, Zetterberg H, Svensson J. Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. *Neurosci Lett*. 2015; 609:58–62. [PubMed: 26453765]
52. Do Carmo S, Cuello AC. Modeling Alzheimer's disease in transgenic rats. *Mol Neurodegener*. 2013; 8:37. [PubMed: 24161192]
53. Campolongo P, Ratano P, Ciotti MT, Florenzano F, Nori SL, Marolda R, et al. Systemic administration of substance P recovers beta amyloidinduced cognitive deficits in rat: involvement of Kv potassium channels. *PLoS One*. 2013; 8:e78036. [PubMed: 24265678]
54. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. *Proc Natl Acad Sci U S A*. 1991; 88:7247–51. [PubMed: 1714596]
55. Liu X, Shu SY, Zeng C, Cai Y, Zhang K, Wang C, et al. The role of substance P in the marginal division of the neostriatum in learning and memory is mediated through the neurokinin 1 receptor in rats. *Neurochem Res*. 2011; 36:1896–902. [PubMed: 21611833]
56. Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. *Curr Drug Targets*. 2006; 7:975–92. [PubMed: 16918326]
57. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. *Expert Opin Investig Drugs*. 2007; 16:1977–85.
58. Chauhan VS, Sterka DG, Gray DL, Bost KL, Marriott I. Neurogenic exacerbation of microglial and astrocyte responses to *Neisseria meningitidis* and *Borrelia burgdorferi*. *J Immunol*. 2008; 180:8241–9. [PubMed: 18523290]

59. Parthasarathy G, Philipp MT. The MEK/ERK pathway is the primary conduit for *Borrelia burgdorferi*-induced inflammation and P53-mediated apoptosis in oligodendrocytes. *Apoptosis*. 2014; 19:76–89. [PubMed: 24114360]
60. Maddahi A, Edvinsson L. Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. *J Neuroinflammation*. 2010; 7:14. [PubMed: 20187933]
61. Chernova I, Lai J-P, Li H, Schwartz L, Tuluc F, Korchak HM, et al. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). *J Leukoc Biol*. 2009; 85:154–64. [PubMed: 18835883]
62. Robinson P, White AC, Lewis DE, Thornby J, David E, Weinstock J. Sequential expression of the neuropeptides substance P and somatostatin in granulomas associated with murine cysticercosis. *Infect Immun*. 2002; 70:4534–8. [PubMed: 12117965]
63. Vinet-Oliphant H, Alvarez X, Buza E, Borda JT, Mohan M, Aye PP, et al. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. *Am J Pathol*. 2010; 177:1286–97. [PubMed: 20671267]
64. Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. *Proc Natl Acad Sci U S A*. 2001; 98:3970–5. [PubMed: 11274418]
65. Wang X, Douglas SD, Lai J-P, Tuluc F, Tebas P, Ho W-Z. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. *J Neuroimmune Pharmacol*. 2007; 2:42–8. [PubMed: 18040825]
66. Podda G, Nyirenda M, Crooks J, Gran B. Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis. *J Neuroimmune Pharmacol*. 2013; 8:791–806. [PubMed: 23812895]
67. Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brueck W, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist—a putative role for substance P in CNS inflammation. *J Neuroimmunol*. 2006; 179:1–8. [PubMed: 16904192]
68. Thornton E, Tran TTB, Vink R. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. *Neurosci Lett*. 2010; 481:64–7. [PubMed: 20599590]
69. Thornton E, Vink R. Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. *Neural Regen Res*. 2015; 10:1403–5. [PubMed: 26604896]
70. Thornton E, Hassall MM, Corrigan F, Vink R. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemiparkinsonian rodent model. *Parkinsonism Relat Disord*. 2014; 20:508–13. [PubMed: 24637127]
71. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, et al. Tachykinins and tachykinin receptors: structure and activity relationships. *Curr Med Chem*. 2004; 11:2045–81. [PubMed: 15279567]